Experimental squalene adjuvant

Süli, Judit; Benísek, Z; Eliáš, Daniel; Svrcek, S; Ondrejková, Anna; Ondrejka, R.; Bajová, Viera

doi:10.1016/j.vaccine.2004.02.023

Cited by 13 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One such system (10% squalene, 1.8% glycerol, 1.9% phosphatidylcholine, 0.09% Pluronic F68) was shown to increase the immunogenicity of an inactivated trivalent poliovirus vaccine [142]. Another one (5% squalene, 4% Poloxamer 105 and 2% Abil-Care as emulsifier) increased the immunogenicity of non-potentiated rabies vaccine, more effective than aluminum hydroxide [143]. CoVaccineHTTM, a submicron emulsion of squalene-in-water emulsion containing sucrose fatty acid sulphate esters, has been shown to increase the antibody responses for a whole inactivated influenza A/ H5N1 virus vaccine through TLR4 signaling in mice [144].…”

Section: Emulsionsmentioning

confidence: 99%

See 1 more Smart Citation

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

Section: Emulsionsmentioning

confidence: 99%

“…CEL-1000 (18-mer) is an analogue of peptide G (a peptide from human MHCII beta chain, aa [135][136][137][138][139][140][141][142][143][144][145][146][147][148][149], which is known to enhance immune responses of other immunogenic peptides. They can be conjugated to HIV (HGP-30) and malaria peptides as potential vaccines.…”

Section: Specific Peptides/proteinsmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…Experimental squalene adjuvant (ESA) is composed, upon injection, of 5% w/v squalene, 4% w/v Pluronic ® L35, and 2% w/v of the surfactant Abil ® -Care (polysiloxan polymer dimethicone copolyol), with a particle size of 200 nm [ 87 ]. The antigen is emulsified with the emulsion under mild conditions.…”

Section: Vaccinesmentioning

confidence: 99%

“…Although much less toxic than mineral oil adjuvants, the reactogenicity of Montanide ® ISA 720 may be cause for concern and is currently under investigation [ 83 , 96 , 97 , 98 ]. Another w/o squalene emulsion is TiterMax ® Classic, which contains squalene, Tween ® 80, the block copolymer CRL-8941 (Pluronic ® L141), and silica microparticles coated with CRL-8941 [ 87 , 99 , 100 , 101 ]. Generally, a 50% v/v squalene content is injected but this can be reduced to as low as 10% [ 101 ].…”

Section: Vaccinesmentioning

confidence: 99%

Squalene Emulsions for Parenteral Vaccine and Drug Delivery

2009

View full text Add to dashboard Cite

Squalene is a linear triterpene that is extensively utilized as a principal component of parenteral emulsions for drug and vaccine delivery. In this review, the chemical structure and sources of squalene are presented. Moreover, the physicochemical and biological properties of squalene-containing emulsions are evaluated in the context of parenteral formulations. Historical and current parenteral emulsion products containing squalene or squalane are discussed. The safety of squalene-based products is also addressed. Finally, analytical techniques for characterization of squalene emulsions are examined.

show abstract

“…[4][5][6][7][8] Currently, there are 2 squalene emulsion adjuvants approved for clinical use in Europe: MF59 Ò9-11 (Novartis Vaccines & Diagnostics), and AS03 11,12 (GSK Biologics; AS03 is also approved in the US for the use with a 2009 pandemic flu vaccine). Both these emulsions contain a squalene content of around 2-4% (w/w) with additional emulsifying agents.…”

Section: Introductionmentioning

confidence: 99%

Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants

Iyer

Cayatte

Guzman

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Oil-in-water emulsions have gained consideration as vaccine adjuvants in recent years due to their ability to elicit a differentiated immunogenic response compared to traditional aluminum salt adjuvants. Squalene, a cholesterol precursor, is a natural product with immunostimulatory properties, making it an ideal candidate for such oil-in-water emulsions. Particle size is a key parameter of these emulsions and its relationship to stability and adjuvanticity has not been extensively studied. This study evaluates the effect of particle size on the stability and immunogenicity of squalene emulsions. We investigated the effect of formulation parameters such as surfactant concentration on particle size, resulting in particles with average diameter of 80 nm, 100 nm, 150 nm, 200 nm, or 250 nm. Emulsions were exposed to shear and temperature stresses, and stability parameters such as pH, osmolarity, size, and in-depth visual appearance were monitored over time. In addition, adjuvanticity of different particle size was assessed in a mouse model using Respiratory Syncytial Virus Fusion protein (RSV-F) as a model antigen. Temperature dependent phase separation appeared to be the most common route of degradation occurring in the higher particle sizes emulsions. The emulsions below 150 nm size maintained stability at either 5 C or 25 C, and the 80 nm diameter ones showed no measurable changes in size even after one month at 40 C. In vivo studies using the emulsions as an adjuvant with RSV F antigen revealed that superior immunogenicity could be achieved with the 80 nm particle size emulsion.

show abstract

Experimental squalene adjuvant

Cited by 13 publications

References 19 publications

Selection of Adjuvants for Enhanced Vaccine Potency

Selection of Adjuvants for Enhanced Vaccine Potency

Squalene Emulsions for Parenteral Vaccine and Drug Delivery

Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants

Contact Info

Product

Resources

About